Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit Jan Schuurhuis, Gert J. Ossenkoppele, Michael Heuser et al.|Blood|2018Cited by 1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Jacqueline Cloos, Sylvie Freeman et al.|Blood|2021Cited by 714
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S. Hourigan, Mitchell E. Horwitz, Laura W. Dillon et al.|Journal of Clinical Oncology|2019Cited by 441
The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Naval Daver, Juliana Hidalgo Lopez et al.|Cancer|2018Cited by 339
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Michael Heuser, Peter J.M. Valk et al.|Blood|2025Cited by 22